The five-year deal will see the parties work collaboratively to facilitate the manufacture of viral vector based vaccinesOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.